서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 61 to 113 of 113

Issue DateTitle / Author(s) / CitationFileAltmetrics
2011-03
Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer
DOI
2011-04
Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy

Kim, Ji-Won; Lee, Jeong-Ok; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

American Journal of Clinical Oncology, Vol.34 No.2, pp.125-129

DOI
2011-05
Diagnostic performance of contrast enhanced CT and 18F-FDG PET/CT in suspicious recurrence of biliary tract cancer after curative resection
DOI
2011-06
Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
DOI
2011-06
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
DOI
2011-07
Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study

Shin, Dong-Yeop; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Cancer Chemotherapy and Pharmacology, Vol.68 No.1, pp.165-175

DOI
2011-07
Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins
DOI
2011-09
Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy
DOI
2011-09
VEGF Expression is Related to Good Response and Long Progression-free Survival in Gastrointestinal Stromal Tumor Patients Treated With Sunitinib
DOI
2011-10
Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
DOI
2011-10
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting

Lim, Kyu-Hyoung; Kim, Tae-Yong; Lee, Kyung-Hun; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue

Cancer Chemotherapy and Pharmacology, Vol.68 No.4, pp.1017-1026

DOI
2012-01
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment
DOI
2012-02
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
DOI
2012-02
Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy
DOI
2012-03
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells
DOI
2012-03
Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cells
DOI
2012-04
NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

Park, Eunju; Park, Jinah; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Oh, Do-Youn; Bang, Yung-Jue

International Journal of Oncology, Vol.40 No.4, pp.1259-1266

DOI
2012-04
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study
DOI
2012-04
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: A long-term single center experience
DOI
2012-07
Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers
DOI
2012-07
Outcome of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (iFAM) Chemotherapy and Analysis of Prognostic Factors in Patients with Refractory Advanced Biliary Tract Cancer
DOI
2012-08
Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer
DOI
2012-09
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer
DOI
2012-09
Distant metastasis risk stratification for patients undergoing curative resection followed by adjuvant chemoradiation for extrahepatic bile duct cancer

Kim, Kyubo; Chie, Eui Kyu; Jang, Jin-Young; Kim, Sun Whe; Han, Sae-Won; Oh, Do-Youn; Im, Seock-Ah; Kim, Tae-You; Bang, Yung-Jue; Ha, Sung W.

International Journal of Radiation Oncology Biology Physics, Vol.84 No.1, pp.81-87

DOI
2012-12
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines
DOI
2013-01
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer
DOI
2013-04
Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases
DOI
2013-05
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer
DOI
2013-06
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
DOI
2013-07
OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
DOI
2013-12
Clinical Implications of VEGF, TGF-beta 1, and IL-1 beta in Patients with Advanced Non-small Cell Lung Cancer
DOI
2013-12
The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer
view filelink
2014-07
A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions
DOI
2015-01
KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX
DOI
2015-03
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
view fileDOI
2015-06
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer
DOI
2015-06
Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer
DOI
2015-08
Metabolic characteristics of advanced biliary tract cancer using F-18-fluorodeoxyglucose positron emission tomography and their clinical implications
DOI
2015-10
The prognostic importance of the number of metastatic lymph nodes for patients undergoing curative resection followed by adjuvant chemoradiotherapy for extrahepatic bile duct cancer
DOI
2016-04
Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer patients in stage II in the 7th TNM but stage I in the 6th TNM system?
DOI
2016-06
Prognostic role of body mass index in advanced small bowel adenocarcinoma patients receiving palliative chemotherapy
DOI
2016-07
Src as a Therapeutic Target in Biliary Tract Cancer
DOI
2016-08
Prognostic Significance of Nodal Ratio in Patients Undergoing Adjuvant Chemoradiotherapy After Curative Resection for Ampullary Cancer
DOI
2017-04
Phosphorylated Akt expression as a favorable prognostic factor for patients undergoing curative resection and adjuvant chemoradiotherapy for proximal extrahepatic bile duct cancer
DOI
2017-04
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
DOI
2017-12
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
DOI
2017-12
Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy

Kim, Yi-Jun; Koh, Hyeon Kang; Chie, Eui Kyu; Oh, Do-Youn; Bang, Yung-Jue; Nam, Eun Mi; Kim, Kyubo

International Journal of Clinical Oncology, Vol.22 No.6, pp.1069-1075

DOI
2018-07
Phase 1 studies of poziotinib, an irreversible pan-her tyrosine kinase inhibitor in patients with advanced solid tumors
DOI
2020-01
The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy
DOI
2020-02
Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts
DOI
2020-10
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer
DOI
2022-08
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
DOI
2023-02
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
view fileDOI
1 2